Ewing sarcoma cells express RANKL and support osteoclastogenesis

Journal of Pathology

Volumn 225, Issue 2, 2011, Pages 195-202

  Taylor, Richard ^a   Knowles, Helen J ^a   Athanasou, Nicholas A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

bone resorption; Ewing sarcoma; osteoclast; osteoclastogenesis; osteolysis; RANKL

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CD14 ANTIGEN; CD68 ANTIGEN; CD99 ANTIGEN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE RECEPTOR; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BIOASSAY; BONE MATRIX; BONE MINERAL; CANCER CELL CULTURE; CASE REPORT; CELL CONTACT; CELL DIFFERENTIATION; CHILD; COCULTURE; CULTURE MEDIUM; DENTIN; EWING SARCOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; OSTEOCLAST; OSTEOCLASTOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA CELL; TISSUE CULTURE; TISSUE MICROARRAY; WESTERN BLOTTING;

ADOLESCENT; ADULT; BLOTTING, WESTERN; BONE NEOPLASMS; CELL DIFFERENTIATION; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; OSTEOCLASTS; OSTEOLYSIS; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, EWING'S; TISSUE ARRAY ANALYSIS;

EID: 80052455224     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2869     Document Type: Article

References (45)

1. Ushigome S, Machinani R, Sorever P,. Ewing sarcoma. In Pathology and Genetics of Tumours of Soft Tissue and Bone, Fletcher C, Unni K, Mertens F, (eds). IARC: Lyon, 2002; 298-300.
2. Unni K, Inwards C, Bridge J, et al., Tumours of the bones and joints. AFIP Atlas of Tumour Pathology Fourth Series. American Registry of Pathology: Washington, DC, 2005; 281-298.
3. Clohisy DR, Ramnaraine MLR,. Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res 1998; 16: 660-666. (Pubitemid 29021895)
4. Clohisy DR, Ogilvie CM, Carpenter RJ, et al., Localised tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J Orthop Res 1996; 14: 2-6. (Pubitemid 26091596)
5. Quinn J, Sabokbar A, Athanasou NA,. Cells of the mononuclear phagocyte series differentiate into osteoclastic lacunar bone-resorbing cells. J Pathol 1996; 179: 106-111. (Pubitemid 26180087)
6. Fujikawa Y, Quinn JMW, Sabokbar A, et al., The human mononuclear osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996; 139: 4058-4060. (Pubitemid 26284685)
7. Yang TT, Sabokbar A, Gibbons CML, et al., Human mesenchymal tumour-associated macrophages differentiated into osteoclastic bone resorbing cells. J Bone Joint Surg 2002; 84B: 452-456. (Pubitemid 34413781)
8. Lau YS, Sun SG, Gibbons CMLH, et al., Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. Br J Cancer 2007; 89: 928-932.
9. Tanaka S, Takahashi N, Udagawa N, et al., Macrophage colony stimulating factor is indispensable for both the proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993; 91: 257-263. (Pubitemid 23037280)
10. Yasuda H, Shima N, Nakagawa N, et al., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-3602.
11. Sun SG, Lau YS, Itonaga I, et al., Bone stromal cells in Paget's disease and Paget's sarcoma express RANKL and support human osteoclast formation. J Pathol 2006; 209: 114-120.
12. Athanasou NA, Puddle B, Quinn J, Woods CG,. Use of monoclonal antibodies to recognise osteoclasts in routinely processed bone biopsy specimens. J Clin Pathol 1991; 44: 664-666.
13. Minkin C,. Bone acid phosphatise: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982; 34: 285-290. (Pubitemid 12060442)
14. Eilon G, Mundy GR,. Direct resorption of bone by human breast cancer cells in vitro. Nature 1978; 276: 726-728. (Pubitemid 9073534)
15. Carter RL,. Patterns and mechanisms of bone metastases. J R Soc Med 1985; 78 (Suppl 9): 2-6.
16. Galasko CSB,. Mechanisms of bone destruction in the development of skeletal metastases. Nature 1976; 263: 507-508.
17. Galasko CSB,. Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop Relat Res 1982; 169: 20-27. (Pubitemid 12021006)
18. Fukushima H, Novak JF, McMaster JH, et al., Bone resorption in osteogenic sarcoma. 1. Release of calcium by tumour cells, normal fibroblasts, and macrophages. Clin Orthop Relat Res 1983; 180: 268-277. (Pubitemid 14233119)
19. Chambers TJ, Darby JA, Fuller K,. Mammalian collagenase predisposes bone surfaces to osteoclastic resorption. Cell Tissue Res 1985; 241: 671-675. (Pubitemid 15024615)
20. Novak JF, Fukushima H, McMaster JH, et al., Bone resorption in osteogenic sarcoma-II. Resorption of the bone collagenous matrix by tumour cells, normal fibroblasts and macrophages. Eur J Cancer Clin Oncol 1984; 20: 939-946. (Pubitemid 14086920)
21. OH Sanchez-Sweatman, Lee J, Orr FW, et al., Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur J Cancer 1997; 13: 918-925. (Pubitemid 27288578)
22. Morgan H, Hill PA,. Human breast cancer cell-mediated bone collagen degradation requires plasminogen activater and matrix metalloproteinase activity. Cancer Cell Int 2005; 5: 1-10.
23. Mundy GR, Varani J, Orr W, et al., Resorbing bone is chemotactic for monocytes. Nature 1978; 275: 132-135. (Pubitemid 9006937)
24. Mantovani A, Botlazzi B, Coloth F, et al., The origin and function of tumour-associated macrophages. Immunol Today 1992; 13: 265-276.
25. Quinn JMW, McGee JOD, Athanasou NA,. Human tumour-associated macrophages differentiate into osteoclastic bone resorbing cells. J Pathol 1998; 184: 31-36. (Pubitemid 28086150)
26. Kitazawa S, Kitazawa R,. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 2002; 198: 228-236. (Pubitemid 35243881)
27. Zhang J, Dai J, Qi Y, et al., Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235-1244. (Pubitemid 32494540)
28. Fernandez M, Pino AM, Figueroa P, et al., The increased expression of receptor activator of nuclear-κB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate. J Cell Biochem 2010; 111: 130-137.
29. Riggi N, Cironi L, Provero P, et al., Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005; 65: 11459-11468. (Pubitemid 41821703)
30. Hameed M,. Small round cell tumours of bone. Arch Pathol Lab Med 2007; 131: 192-204.
31. Bu R, Borysenko CW, Li Y, et al., Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone 2003; 33: 760-770. (Pubitemid 37393487)
32. Rube CE, van Valen F, Wilfert F, et al., Ewing's sarcoma and peripheral primitive neuroectodermal tumor cells produce large quantities of bioactive tumor necrosis factor-alpha (TNF-alpha) after radiation exposure. Int J Radiat Oncol Biol Phys 2003; 56: 1414-1425. (Pubitemid 36842895)
33. Zhu H, Jiang XX, Guo ZK, et al., Tumour necrosis factor-alpha alters the modulatory effects of mesenchymal stem cells on osteoclast formation and function. Stem Cells Dev 2009; 18: 1473-1484.
34. Kudo O, Fujikawa Y, Itonaga I, et al., Proinflammatory cytokine (TNFα) induction of human osteoclast formation. J Pathol 2002; 198: 220-227. (Pubitemid 35243880)
35. Avnet S, Longhi A, Salerno M, et al., Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol 2008; 33: 1231-1238.
36. Yagiz K, Rittling SR,. Both cell-surface and secreted CSF-1 expressed by tumour cells metastatic to bone can contribute to osteoclast activation. Exp Cell Res 2009; 315: 2442-2452.
37. Hume DA, Sasmono T, Himes SR, et al., The Ewing sarcoma protein (EWS) binds directly to the proximal elements of the macrophage-specific promoter of the CSF-1 receptor (csflr) gene. J Immunol 2008; 180: 6733-6742.
38. Picarda G, Lamoureux F, Geffroy L, et al., Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res 2010; 16: 2363-2374.
39. Russell RG, Xia Z, Dunford JE, et al., Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007; 1117: 209-257. (Pubitemid 350191297)
40. Russell G,. Bisphosphonate: mode of action and pharmacology. Pediatrics 2007; 119: S150-S162.
41. Petra M, Gibbons CLMH, Athanasou NA,. Bisphosphonate treatment of benign multifocal and unifocal primary osteolytic tumours of bone. Sarcoma 2003; 7: 35-41. (Pubitemid 36577845)
42. Balke M, Campanacci L, Gebert C, et al., Bisphosphonate treatment of giant cell tumour of bone. BMC Cancer 2010; 29: 462-469.
43. Zhou Z, Guan H, Duan X, et al., Zoledronic acid inhibits primary bone tumour growth in Ewing sarcoma. Cancer 2005; 104: 1713-1720. (Pubitemid 41437436)
44. Odri G, Dumoucel S, Picarda G, et al., Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 2010; 70: 7610-7619.
45. Thomas D, Henshaw R, Skubitz K, et al., Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11: 275-280.